Abdool Karim, M.B., Ch.B., Ph.D., Quarraisha Abdool Karim, Ph.D., Ayesha B.M. Kharsany, Ph.D., Cheryl Baxter, Ph.D., Anneke C. Grobler, Ph.D., Lise Werner, M.Sc., Angela Kashuba, Pharm.D., Leila E. Mansoor, Ph.D., Natasha Samsunder, B.Tech., Adrian Mindel, M.D., and Tanuja N. Gengiah, Ph.D. For the CAPRISA 004 Trial Group: Tenofovir Gel for the Prevention of HERPES VIRUS Type 2 Infection Globally, herpes virus type 2 infection has become the common sexually transmitted infections and is the leading cause of genital ulcers.We found that a notable difference in antifungal therapy through the first 2 weeks of a 10-week treatment was associated with a survival benefit at six months. Between 10 weeks and six months, 4 extra deaths occurred in sufferers receiving amphotericin B plus flucytosine, versus 9 and 12 deaths in patients receiving amphotericin B by itself and those getting amphotericin B plus fluconazole, respectively. The sources of death in these individuals were unclear, because so many sufferers had returned with their home provinces. The low death rate among individuals receiving flucytosine, as compared with the price among those receiving amphotericin B monotherapy, may have been due to lower prices of disability in these patients, which safeguarded them from further problems, or lower rates of disease relapse, an association that is previously identified.24,25 In conclusion, the results of the study suggest that initial combination therapy with amphotericin B and flucytosine for 2 weeks inside our setting was associated with reduced mortality among patients with HIV-associated cryptococcal meningitis, in comparison with 4 weeks of amphotericin B monotherapy.